Patient P-02142
Therapy response
Declining
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
95%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −20% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 71 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 74 GI-04 recommended — GI Support Protocol GI-04
- Day 75 Patient accepted — Started GI-04 in the companion
- Day 83 GI symptom burden −34% vs expected — GI Support Protocol GI-04
- Day 89 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 71.
Primary contributors, last 14 days
- Nutritional resilience-18
- GI instability+16
- Inflammatory activity+11
- Toxicity+11
- Treatment adherence+2
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −20%
- GI Support Protocol GI-04Day 74Result: symptom burden −34%
LIFE OS recommendation
Monitoring Escalation ME-01
91%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 59
- WearableHRV 21 ms, trending down
- Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable3,243 steps/day
- WearableShort sleep window
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 64 and rising
- WearableSleep 5.6 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 41/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑20
- BloodToxicity index 53
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.3 · butyrate capacity 41/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 26 ms
- Sleep
- 6.0 h
- Steps
- 3,767
- Resting HR
- 81 bpm
Daily log: GI score 64, nutritional resilience 31, adherence 49.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02149 | 57% | S14 | GI-04 | improved | 50 |
| P-02159 | 53% | S14 | GI-04 | improved | 47 |
| P-02236 | 52% | S14 | GI-04 | improved | 45 |
| P-02445 | 47% | S09 | GI-04 | improved | 43 |
| P-02648 | 47% | S14 | SC-12 | improved | 47 |
| P-02542 | 45% | S14 | NP-02 | improved | 44 |
| P-02185 | 44% | S14 | GI-04 | improved | 51 |
| P-02002 | 42% | S14 | GI-04 | improved | 47 |
| P-02018 | 42% | S01 | GI-04 | improved | 46 |
| P-02103 | 42% | S14 | GI-04 | improved | 46 |
| P-02108 | 42% | S14 | GI-04 | improved | 43 |
| P-02125 | 42% | S14 | GI-04 | improved | 55 |